Probable neurotoxin with unknown target (Probable). Possibly targets ion channels (Probable). This peptide could be considered as a potential apoptosis activator in some cancers (tested on lung and breast cancer cell lines) (Probable). When treated with this synthetic peptide, lung cancer cell lines have decreased cell viability, activated caspases, and reduced expression of the pro-survival protein NF-kappa-B (NFKB1) (PubMed:26861394). In synergy with MicroRNA-101-3p, this synthetic peptide inhibits breast cancer cells through suppressing the expression of the methyltransferase EZH2 (PubMed:33061442). Against microbes, this synthetic toxin (at micromolar concentrations) lowers viability and inhibits host cell invasion by the opportunistic parasite Toxoplasma gondii (tachyzoite form) (PubMed:27070627). In addition, it permits T.gondii intracellular replication to decrease while viability of the host cell is unaffected (PubMed:27070627). Expressed by the venom duct. The cysteine framework is XIV (C-C-C-C). Contains 2 disulfide bonds. Belongs to the conotoxin L superfamily. Submitted sequence does not correspond to the one indicated in the paper. It may have been erroneously substituted by that of conotoxin Cl14.2c.